MedTrace Logo

Novel Treatment for Patients With Peanut Allergy: Intralymphatic Immunotherapy

NCT04200989 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2022-11-22

No results posted yet for this study

Summary

Use of three intralymphatic injections of peanut allergen one month apart to induce tolerance to peanut in peanut allergic people.

Conditions

  • Food Allergy Peanut

Interventions

BIOLOGICAL

Peanut allergen

Intralymphatic immunotherapy injections.

Sponsors & Collaborators

  • The Scripps Research Institute

    collaborator OTHER

  • Scripps Health

    lead OTHER

Principal Investigators

  • Simon A Ronald, MD · Scripps Health

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
15 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2021-12-31
Completion
2021-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04200989 on ClinicalTrials.gov